ARA-290 (cibinetide) research: what the trials show

ARA-290, known in trials as cibinetide, is an 11-amino-acid peptide designed from erythropoietin that has reached randomized human testing. Here is what the published trials found.

Findings

  • A 64-subject phase 2b trial met its primary endpoint: corneal nerve fibre area rose by 697 square micrometres against placebo in the 4 mg group over 28 days (p=0.012).
  • In a randomized pilot in sarcoidosis, the symptom score improved by 11.5 points against 2.9 on placebo (p<0.05).
  • A 28-day blinded trial reported a significant increase in corneal small nerve fibre density and greater distance on the six-minute walk test.
  • In type 2 diabetes, 28 days of ARA-290 improved HbA1c and lipid profiles across a 56-day observation period, with neuropathic symptom scores also improving.
  • Across all four trials, no safety concerns were raised by clinical or laboratory assessment.

Sarcoidosis small fibre neuropathy: the first randomized signal (Mol Med, 2012)

Twenty-two people with sarcoidosis and symptoms of small fibre neuropathy were randomized to intravenous ARA-290 at 2 mg three times a week (12 patients) or placebo (10 patients) for four weeks. At week four, the small fibre neuropathy screening list score fell by 11.5 points in the treated group against 2.9 on placebo, a significant difference. The pain and physical functioning dimensions of the SF-36 quality-of-life questionnaire also improved from baseline in the treated group. Clinical and laboratory assessments raised no safety concerns.

Nerve fibre density and walking distance (Mol Med, 2013)

A blinded, placebo-controlled trial gave patients with documented small nerve fibre loss daily subcutaneous ARA-290 for 28 days. Alongside the improvement in patient-reported symptoms, the authors measured a significant increase in corneal small nerve fibre density, changes in skin temperature sensitivity, and increased exercise capacity on the six-minute walk test. Those are objective measures of the nerve fibres themselves, not only of how patients felt.

Phase 2b: the primary endpoint (Invest Ophthalmol Vis Sci, 2017)

The largest trial randomized 64 subjects with sarcoidosis-associated small nerve fibre loss and neuropathic pain to cibinetide at 1, 4 or 8 mg a day, or placebo, for 28 days. The primary endpoint was the change in corneal nerve fibre area, measured by corneal confocal microscopy. The 4 mg group gained 697 square micrometres against placebo (95% confidence interval 159 to 1236, p=0.012). Regenerating fibres in the skin, marked by GAP-43, increased in the same group (p=0.035), and the change in corneal nerve fibre area tracked the change in walking distance (rho 0.645, p=0.009). The authors read the combination as consistent with a disease-modifying effect.

Type 2 diabetes: nerves and metabolic markers (Mol Med, 2015)

In a phase 2 study, subjects with type 2 diabetes and painful neuropathy self-administered ARA-290 at 4 mg or placebo daily for 28 days, then were followed for a further month with no treatment. The treated group showed improvement in HbA1c and lipid profiles across the whole 56-day observation period, and neuropathic symptoms measured by the PainDetect questionnaire improved significantly. Subjects whose corneal nerve fibre density was furthest below normal at the start showed a significant increase, against no change on placebo. No safety issues were identified.

What ARA-290 is

ARA-290 is an 11-amino-acid peptide built from a region of the erythropoietin molecule that sits away from the part responsible for making red blood cells. It binds the innate repair receptor, a receptor studied for tissue protection, control of inflammation and repair, which is why the trials above measured nerve fibres rather than blood counts. Our ARA-290 reconstitution guide covers handling of the research material.

Vistara Labs stocks ARA-290 research vials, shipped from within Canada to every province.

Frequently asked questions

Has ARA-290 been tested in humans?

Yes. ARA-290, also called cibinetide, has been through four published randomized trials in people with sarcoidosis-associated small nerve fibre loss and in type 2 diabetes, including a 64-subject phase 2b trial that met its primary endpoint.

What did the corneal nerve measurements show?

In the 28-day phase 2b trial, the 4 mg group gained 697 square micrometres of corneal nerve fibre area against placebo (95% confidence interval 159 to 1236, p=0.012). Regenerating fibres in the skin increased in the same group (p=0.035).

What is ARA-290?

ARA-290 is an 11-amino-acid peptide designed from a region of erythropoietin. It activates the innate repair receptor, which is studied for tissue protection and control of inflammation, without the red-blood-cell effects of erythropoietin itself.

Sources: Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18:1430-6. PMID 23168581. Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19:334-45. PMID 24136731. Culver DA, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2017;58:BIO52-BIO60. PMID 28475703. Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20:658-66. PMID 25387363.

All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.

Similar Posts